
GENMAB AS DK 1
Share · DK0010272202 · 565131 (XCSE)
194,70 EUR
12.06.2025 06:07
Current Prices from GENMAB AS DK 1
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() Frankfurt |
GE9.F
|
EUR
|
12.06.2025 06:07
|
194,70 EUR
| 199,00 EUR
-2,16 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
-0,75 % | 1,04 % | 10,00 % | 5,07 % | -5,26 % | -21,01 % | -27,24 % |
Profil de l'entreprise pour GENMAB AS DK 1 Action
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Fonds investis
Les fonds suivants ont investi dans : GENMAB AS DK 1 investi :
Fonds | Vol. en millions 832,16 | Part (%) 1,91 % |
Fonds | Vol. en millions 1.158,01 | Part (%) 1,35 % |
Fonds | Vol. en millions 110,52 | Part (%) 1,35 % |
Fonds | Vol. en millions 175,99 | Part (%) 1,14 % |
Fonds | Vol. en millions 7.713,76 | Part (%) 1,10 % |
Données de l'entreprise
Nom GENMAB AS DK 1
Société Genmab A/S
Site web
https://www.genmab.com
Marché d'origine
NASDAQ COPENHAGEN A/S
WKN 565131
ISIN DK0010272202
Type de titre Action
PDG Dr. Jan G.J. van de Winkel Ph.D.
Capitalisation boursière 11 Mrd.
Pays Danemark
Devise EUR
Employés 2,7 T
Adresse Carl Jacobsens Vej 30, 2500 Copenhagen
Date d'introduction en bourse 2000-10-23
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | GE9.F |
Autres actions
Les investisseurs qui détiennent GENMAB AS DK 1 ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.